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Abstract
Background: MicroRNAs (miRNAs) have been proved involved in many tumorigenic behaviors including tumor
growth. But, the clinical significance and functions of miRNA-203 in gastric cancer (GC) remain elusive.
Results: Decreased expression of miRNA-203 was correlated with tumor size, poor prognosis and recurrence in GC
patients. Overexpression of miR-203 or knockdown of its target progesterone immunomodulatory binding factor 1
(PIBF1) inhibited GC growth in vitro and in vivo, while miR-203 knockdown promoted GC proliferation. In addition,
PIBF1 overexpression attenuated the inhibitory effects of miR-203 on GC growth and enhanced that effect on p-Akt
expression.
Conclusions: MiR-203 as a tumor biomarker suppresses GC growth through targeting the PIBF1/Akt signaling,
suggesting that it may have the important therapeutic potential for the treatment of GC.
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Background
Gastric carcinoma (GC) is the third leading causes of
cancer-related deaths in the worldwide [1]. It is known
that high recurrence rate and rapid tumor growth have
become the major disturbance to improve the survival of
GC. Though, the treatment strategies of GC, such as
surgical resection and chemotherapy, are effective way
to increase therapeutic outcome, GC patients still have
high risk and mortality [2]. Mounting evidence shows
that many oncogenes or anti-oncogenes are associated
with GC development and progression. However, the
underlying molecular mechanisms of GC are still poorly
understood. Thus, identification of the biomarkers
related to GC growth is urgently needed.
MicroRNAs as small noncoding RNAs of approxi-
mately 18-25 nucleotides are involved in regulation of
cancer development and progression in various types of
cancers, acting as either oncogenes or tumor suppressor
genes [3]. Previous studies have reported that miR-144,
miR-1266, miR-206, MiR-133b, and miR-26a function as
tumor suppressors in GC, while miR-196a/196b and
miR-301a function as the oncogenes in GC and colorec-
tal cancer [4–10]. Circulating miR-203 represents the
potential biomarker for evaluating the lymphatic node
status of cervical cancer patients [11] and regulates epi-
thelial to mesenchymal transition [12]. MiR-203 inhibits
the proliferation and migration in esophageal cancer
cells [13] and decreases nasopharyngeal carcinoma radio
resistance by targeting IL-8/Akt signaling [14]. But, few
studies indicate that upregulation of miR-203 enhances
the malignancy of hypopharyngeal squamous cell carcin-
oma [15]. The correlation of miR-203 expression with
GC has not been reported.
To confirm the relationship of miR-203 expression
with GC growth, we previously identified differentially
expressed miRNAs between GC tissues and adjacent
non-tumor tissues (ANTT). MiRNA expression profiles
showed that miR-203 was significantly downregulated
in GC tissues. It has been manifested that miR-203 is
abnormally expressed in different tumors including
breast cancer, GC, cervical cancer, melanoma, human
glioma, esophageal cancer and lung cancer, and its
down-regulation is implicated in promoting cell prolif-
eration, invasion and metastasis in multiple cancer cells
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[16–25]. But, the contribution of miR-203 to GC growth
is still unclear.
In the present study, our studies demonstrated that
decreased expression of miR-203 predicted poor progno-
sis and recurrence in GC patients and miR-203 overex-
pression or knockdown of its target PIBF1 inhibited cell
proliferation and the colony formation of GC cells by
inhibition of Akt signaling. Our findings suggested that
miR-203 might function as the tumor suppressor in
human GC growth by targeting the PIBF1/Akt signaling.
Methods
Materials
Human GC tissues and the ANTT were collected from
Shanghai Jiao Tong University affiliated Shanghai Sixth
People’s Hospital. GES-1 and GC cell lines (HGC-27,
MKN-28, MKN-45, MGC-803, AGS, SGC-7901 and
BGC-823) used in these experiments were from La-
boratory of Gastroenterology of Shanghai Sixth People’s
Hospital. Lentivirus-mediated miR-203 overexpression,
miR-203 shRNA or PIBF1 shRNA vector, negative con-
trol vector (NC), and virion-packaging elements were
purchased from Genechem (Shanghai, PR, China); All
antibodies used in this study were purchased from Cell
Signaling Technologies (Beverly, MA, USA).
Drugs and reagents
Dulbecco’s Modified Eagle medium (DMEM) and fetal
bovine serum (FBS) were from Thermo Fisher Scientific
Inc (Waltham, MA, USA); 3-(4,5)-dimethylthiahiazo
(-z-yl)-3,5- di-phenytetrazoliumromide (MTT) was from
Dingguo biology (Shanghai, China); TRIzol Reagent and
Lipofectamine 2000 were from Invitrogen (Carlsbad, CA,
USA); M-MLV Reverse Transcriptase was from Promega
(Madison, WI, USA); SYBR Green Master Mixture was
from Takara (Otsu, Japan); RNase A was from KeyGEN
biology (Nanjing, China). ECL-PLUS/Kit was from GE
Healthcare (Piscataway, NJ, USA).
Clinical samples and data
Tumor tissues were collected from biopsy samples under-
going resection of the primary GC in a total of 100 con-
secutive cases admitted in our hospital from January 2007
to September 2015. The baseline characteristics of the
patients before neo-adjuvant chemotherapy were summa-
rized. Follow-up studies included physical examination,
laboratory analysis, and computed tomography if neces-
sary. Overall survival (OS) was defined as the interval be-
tween the dates of surgery and death. The study was
approved by Medical Ethics Committee of Shanghai
Jiao Tong University and written informed consent was
obtained from the patients or their parents before
sample collection.
MiRNA microarray analysis
MiRNAs were extracted from 3 pairs of GC tissues and
corresponding ANTT samples and hybridized on miRNA
microarray chip containing human miRNA probes found
in the miRNA Registry (http://www.mirbase.org/ accessed
miRBase R16.0, Sept 2010). Microarray chip analysis was
performed by KANGCHEM (Shanghai, PR, China).
Immunohistochemical staining
Anti-PIBF1 antibody was used for immunohistochemical
(IHC) detection of the expression of PIBF1 protein in
GC tissues, whose sections were processed for IHC
analysis. For anti-PIBF1 IHC, unmasking was performed
with 10 mM sodium citrate buffer, pH 6.0, at 90 °C for
30 min. Sections were incubated in 0.03 % hydrogen
peroxide for 10 min at room temperature, to remove
endogenous peroxidase activity, and then in blocking
serum for 30 min at room temperature. Anti-PIBF1 anti-
body was used at a dilution of 1:200. The antibody was
incubated overnight at 4 °C. Sections were then washed
three times for 5 min in PBS. Non-specific staining was
blocked with 0.5 % casein and 5 % normal serum for
30 min at room temperature. Finally, staining was de-
veloped using diaminobenzidine substrate, and sections
were counterstained with hematoxylin. Normal serum
or PBS was used to replace PIBF1 antibody in negative
control. PIBF1 expression was semi-quantitatively counted
as the total IHC staining scores [26].
Construction of vectors
A fragment of miR-203 was generated by using the
following primers: sense, 5’- GAATTCGGCGTGTCCC
TTGACCC-3’ and antisense, 5’- CTCGAGGGAGGAG
GGGAATGTGCA-3’ and inserted into the pMD-18 T
vector with a green fluorescent protein reporter gene
within the EcoRI/XhoI restriction sites. The aforemen-
tioned miR-203 plasmid pCDNA3-GFP was transfected
into 293 T cells, and the lentiviral particle-enriched super-
natant was obtained 48 h later. A scrambled sequence
(5’-TTCTCCGAACGTGTCACGT-3’), which had no
homology with the human gene, was used as a scram-
bled negative control.
Cell culture and lentiviral infections
GC cells were cultured in DMEM medium supplemented
with 10 % heat-inactivated FBS, 100 U/ml of penicillin,
and 100 μg/ml of streptomycin. Cells in this medium were
placed in a humidified atmosphere containing 5 % CO2 at
37 °C. On the day of transduction, GC cells were replated
at 5 × 104 cells/well in 24-well plates containing serum-
free growth medium with polybrene (5 mg/ml). Cells were
transfected with recombinant experimental virus or con-
trol virus, and cultured at 37 °C and 5 % CO2 for 4 h.
Then supernatant was discarded and serum containing
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growth medium was added. Positive and stable transfec-
tants were selected and expanded for further study.
Quantitative real-time PCR
To quantitatively confirm the mRNA expression levels
of miR-203 in GC tissues, real-time PCR was performed.
Total RNA was extracted from each clone using TRIzol
according to the manufacturer’s protocol. Reverse tran-
scription was carried out using M-MLV and cDNA
amplification was performed using the SYBR Green
Master Mix kit according to the manufacturer’s guide-
lines. Human glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) gene or U6 was used as an endogenous
control. Data were analyzed using the comparative Ct
method (2-△△Ct). Three separate experiments were per-
formed for each clone.
Western blot analysis
GC cells were harvested and extracted using lysis buffer
(Tris-HCl, SDS, Mercaptoethanol, Glycerol). Cell extracts
were boiled for 5 min in loading buffer and then equal
amount of cell extracts were separated on 15 % SDS-
PAGE gels. Separated protein bands were transferred into
polyvinylidene fluoride (PVDF) membranes and the mem-
branes were blocked in 5 % skim milk powder. The pri-
mary antibodies were diluted according to the instructions
of antibodies and incubated overnight at 4 °C. Then,
horseradish peroxidase-linked secondary antibodies were
added at a dilution ratio of 1:1000, and incubated at room
temperature for 2 h. The membranes were washed with
PBS for three times and the immunoreactive bands were
visualized using ECL-PLUS/Kit according to the kit’s in-
struction. The relative protein level in different groups
was normalized to Tubulin concentration. Three separate
experiments were performed for each clone.
Cell viability assay
Cell proliferation was analyzed using the MTT assay.
Briefly, GC cells transfected with miR-203 or PIBF1 shRNA
were incubated in 96-well-plates at a density of 1 × 105 cells
per well with DMEM medium supplemented with 10 %
FBS. Cells were treated with 20 μl of MTT dye and subse-
quently incubated with 150 μl of DMSO for 5 min. The
color reaction was measured at 570 nm using an Enzyme
Immunoassay Analyzer (Bio-Rad, Hercules, CA). The pro-
liferation activity was calculated for each clone.
Colony formation assay
2 × DMEM containing 20 % FBS and 5 × 103 cells was
mixed with equal volume of 0.7 % agarose and immedi-
ately plated in 6-well plates containing an underlayer of
0.5 % agarose made in 1× DMEM supplemented with
10 % FBS. The plates were cultured at 37 °C under 5 %
CO2 for 5 to 7 days. Surviving colonies were counted
and photographed with a Qimaging Micropublisher 5.0
RTV microscope camera (Olympus, Tokyo, Japan).
Dual-luciferase reporter assay
HGC-27 and MGC-823 cells were seeded into 24- well
plates. After 18 ~ 24 h incubation, 1 mg pmirGLO report
vector carrying wild type 3’-UTR or mutated 3’-UTR of
miR-203 targets was co-transfected with 100 pmol
negative control or miR-203 into the GC cells using X-
tremeGENE reagent. 48 h after transfection, fiefl and
Renilla luciferase activities were measured with a Dual-
Luciferase Reporter System (Promega). PmirGLO re-
port vector was used as a positive control.
Animal experiments
Six-week-old female immune-deficient nude mice (BALB/
c-nu) were bred at the laboratory animal facility (Institute
of Chinese Academy of Sciences, Shanghai, China), and
were housed individually in microisolator ventilated cages
with free access to water and food. All experimental pro-
cedures were performed according to the regulations and
internal biosafety and bioethics guidelines of Shanghai Jiao
Tong University and the Shanghai Municipal Science and
Technology Commission. Mice were injected subcutane-
ously with 1 × 105 GC HGC-27 cells in 50 μl of PBS
pre-mixed with an equal volume of Matrigel matrix
(Becton-Dickinson). Mice were monitored daily and de-
veloped a subcutaneous tumor. When the tumor size
reached 5 mm in length, they were surgically removed, cut
into 1-2 mm3 pieces, and re-seeded individually into other
mice. When tumor size reached 5 mm in length, the mice
were randomly classified as miR-NC group and miR-203
group. 15 μl of lentivirus was injected into subcutaneous
tumors using a multi-site injection format. Injections were
repeated every other day after initial treatment. The tumor
volume every three days was measured with a caliper,
using the formula: volume = (length × width)2/2.
Statistical analysis
SPSS 20.0 was used for the statistical analysis. All of the
values were recorded as the mean ± SEM from at least 3
independent experiments. Kruskal-Wallis H test and
Chi-square test were used to analyse the expression rate
in all groups. One-way analysis of variance (ANOVA)
was used to analyze the differences between groups. The
LSD method of multiple comparisons was used when
the probability for ANOVA was statistically signifi-
cant. Statistical significance was set at P < 0.05.
Result
MiR-203 is downregulated in human GC tissue
The miRNA expression profiles showed that miR-203
was down-regulated in GC tissues, compared to the
ANTT (Fig. 1a). To validate this result, we accomplished
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the quantitative Real-time PCR in 100 cases of GC tis-
sues and ANTT. Compared with the 41 cases of ANTT,
miR-203 was markedly lowly-expressed (more than 2-
fold; i.e., log2 [fold change] >1) in 59 cases of GC (P < 0.01;
Fig. 1b). These data suggested that aberrant expression of
miR-203 was a frequent event in human GC tissues. Con-
sistent with the miRNA array data, the expression level of
miR-203 was negatively correlated with the tumor size in
GC patients (Fig. 1c).
Low miR-203 expression is related with clinicopathologic
features, poor prognosis and recurrence in GC patients
We further examined the association between miR-203
expression and clinicopathological features in GC pa-
tients. As shown in Table 1, the results indicated that
miR-203 expression was significantly associated with
tumor size (P = 0.006), but did not correlate with age, sex,
vascular invasion and pathological stage in GC patients
(P > 0.05). Furthermore, we analyzed the relationship be-
tween miR-203 expression and GC patients’ prognosis
and recurrence. Kaplan-Meier and Multivariate analysis
showed that tumor size and miR-203 were the independ-
ent factors of the prognosis (Additional file 1: Table S1)
and recurrence (Additional file 2: Table S2) in GC pa-
tients. Survival curves showed that GC patients with low
Fig. 1 MiR-203 was downregulated in human GC tissue and was correlated with tumor size, overall survival and recurrence in GC patients.
a Cluster analysis of miRNA expression profiles of GC and the ANTT. b Expression level of miR-203 was determined in 100 pairs of GC tissues
and their corresponding ANTT by Real-time PCR and normalized to U6. c The patients were divided into ANTT, tumor size <5 cm and tumor
size >5 cm groups. The diagram showed the miR-203 expression in each group. *P < 0.05. d, e GC patients were divided into low miR-203
expression group and high miR-203 expression group respectively, according to the result of Real-time PCR. Survival and recurrence curves
were drawn with the log-rank test. Results showed the OS and recurrence of GC patients with high or low miR-203 expression
Table 1 The correlation of miR-203 expression with




≤50 33 21 0.644
>50 26 20
Sex
Female 22 18 0.509
Male 37 23
Tumor size (cm)




Yes 33 20 0.483
Pathological staging
I/II 25 24 0.114
III/IV 34 17
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miR-203 expression had shorter OS (Fig. 1d) and higher
recurrence rate (Fig. 1e) than those with high miR-203
expression (Fig. 1d). The 1-, 3-, and 5-year OS rates of GC
patients with low miR-203 expression were 81.8 %, 45.5 %,
and 14.2 %, respectively, while those with high miR-203
expression were (93.5 %, 66.8 %, and 35.6 %, respectively).
The 1-, 3-, and 5-year recurrence rates of the low miR-203
group were 27.9 %, 64.8 %, and 81.3 %, respectively, sig-
nificantly higher than those of the high miR-203 group
(14.5 %, 33.3 %, and 74.2 %, respectively). These results
Fig. 2 MiR-203 inhibited proliferation and colony formation of GC Cells. a Expression levels of miR-203 in a panel of human GC cell lines. b The
expression level of miR-203 in lentivirus-mediated miR-203 infected GC HGC-27 and BGC-823 cells. c, d Proliferative activity of GC cells was detected by
MTT assay at the indicated time after seeding. e, f Effect of miR-203 overexpression on colony formation of GC cells. **P < 0.01
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suggested that decreased expression of miR-203 might be
associated with poor prognosis and recurrence of GC pa-
tients, involved in the progression of GC.
MiR-203 overexpression inhibits proliferation and colony
formation and its knockdown promotes cell proliferation
in GC cells
Having investigated the correlation of miR-203 expres-
sion with tumor size in GC patients (Table 1), we
continued to explore the functions of miR-203 in GC
growth. In our study, we analyzed the expression levels
of miR-203 in a panel of human GC cell lines. The
results showed that HGC-27 and BGC-823 cell lines
with high malignance displayed lower miR-203 expres-
sion levels (Fig. 2a) and were chosen for further func-
tional studies. We used lentivirus-mediated miR-203
overexpression to infect HGC-27 and BGC-823 GC
cells (Fig. 2b). Furthermore, we explored the effects of
miR-203 overexpression on cellular proliferative func-
tions in GC cells by MTT assay and found that miR-
203 overexpression significantly inhibited the growth
of HGC-27 and BGC-823 cells (Fig. 2c, d). Colony
formation assay shows that miR-203 overexpression
decreased cell colony formation in HGC-27 and BGC-823
cells (Fig. 2e, f ).
Moreover, we found that miR-203 knockdown pro-
moted cell growth (Additional file 3: Figure S1A), but
exerted no effect on cell colony formation (Additional
file 3: Figure S1B) in MKN-28 and MGC-803 cells with
high miR-203 expression. We examined the protein
expression levels of PIBF1 and its downstream factors
such as Akt, EGFR and STAT3 by Western blotting.
The results showed that miR-203 knockdown upregu-
lated the protein expression of PIBF1and p-Akt, but
had no effect on the expression of Akt, EGFR and
STAT3 in MKN-28 and MGC-803 cells (Additional
file 3: Figure S1C).
PIBF1 is a novel target of miR-203
To uncover the mechanisms by which miR203 affects
cell growth in GC, we attempted to identify potential
target genes of miR-203. We searched publicly available
miRNA-target prediction websites for potential genes
under the control of miR-203. Among hundreds of
different targets, progesterone immunomodulatory bind-
ing factor 1(PIBF1) seemed to be of particular interest.
To further confirm whether miR-203 could directly bind
to the 3’ UTR of PIBF1, the WT 3’ UTR or the mutant
3’ UTR target sequences (Fig. 3a) were cloned into the
luciferase reporter vector, and transfected into cells with
a referential vector. Our results showed that miR-203
overexpression suppressed both the mRNA (Fig. 3b) and
protein expression level (Fig. 3c) of PIBF1 in HGC-27
and BGC-823 cells. In addition, miR-203 overexpression
inhibited the luciferase activity of WT 3’ UTR of PIBF1
in GC cells (Fig. 3d).
Knockdown of BIBF1 inhibits proliferation and colony
formation of GC cells
To further inquire into the cell proliferative functions of
BIBF1 in GC cell, MTT and colony formation assays were
performed. We found that PIBF1 in HGC-27 and BGC-
823 cells was effectively knocked down by PIBF1 shRNA
in both the mRNA (Fig. 4a) and protein level (Fig. 4b).
Moreover, PIBF1 knockdown significantly reduced the
cells proliferation (Fig. 4c, d) and weakened the colony for-
mation capacity in HGC-27 and BGC-823 cells (Fig. 4e, f ).
Fig. 3 MiR-203 inhibited the luciferase activity of WT 3’UTR of PIBF1 and decreased its mRNA and protein expression levels. a Diagrams showed
the miR-203 putative binding sites and corresponding mutant sites of PIBF1. b, c The expression level of PIBF1 was tested with Real-time PCR and
Western blotting assays in miR-203 and miR-NC groups. d Luciferase activity was determined after miR-203 transfection. Data were normalized to
the luciferase activity after transfection with miR-NC
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MiR-203 suppresses PIBF1-mediated activation of Akt
signaling
Studies have shown that PIBF1 plays its role by regulat-
ing Akt, EGFR, and STAT3 pathways in cancer cells [3].
To further clarify the molecular mechanism by which
PIBF1 contributed to miR-203-induced cell proliferation,
lentivirus-mediated PIBF1 was used to transfect into
miR-203-treated HGC-27 and BGC-823 cells, indicating
that miR-203 depressed cell proliferation via inhibition
of the PIBF1 expression (Fig. 5a, c). Furthermore, we
Fig. 4 Knockdown of PIBF1 inhibited proliferation and colony formation of GC cells. The expression level of PIBF1 was examined by Real-time
PCR (a) and Western blotting (b) in lentivirus-mediated PIBF1 shRNA infected GC HGC-27 and BGC-823 cells. c, d Proliferation activity of GC cells
was evaluated by MTT assay at the indicated time after seeding. e, f Effect of PIBF1 knockdown on colony formation of GC cells. **P < 0.01
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examined the protein expression levels of Akt, EGFR
and STAT3, which were the potential downstream regu-
latory factors of PIBF1 related to cell growth by Western
blotting. The results showed that miR-203 downregulated
the protein expression of p-Akt by inhibition of the PIBF1
expression, but had no effect on the expression of Akt,
EGFR and STAT3 (Fig. 5b). Thus, PIBF1 restoration par-
tially counteracted the tumor suppressive effects of miR-
203 in GC cells.
MiR-203 overexpression inhibited GC growth in vivo
Our findings in vitro indicated that miR-203 overexpres-
sion suppressed the growth of GC cells. Therefore, the
xenograft tumor model was constructed to validate the
tumor growth in vivo. During the whole tumor growth
period, the growth activity of GC was measured. The
tumors of GC appeared significantly smaller in miR-203
group compared with the miR-NC group (Fig. 6a, b).
When the tumors were harvested, the average weight
and volumes of the tumors in miR-203 group were sig-
nificantly smaller than those in si-NC group (**P < 0.01,
Fig. 6c, d). IHC staining was used to further evaluate
the protein expression of PIBF1, Akt, EGFR and STAT3
in GC tissues. We found that the expression levels of
PIBF1 and p-Akt were downregulated in miR-203 group
compared with the miR-NC group, and Akt, EGFR and
STAT3 had no differential expression between miR-203
and miR-NC group (Fig. 6e).
Discussion
High recurrence rate and rapid tumor growth remain
the major cause of increase GC survival rate. Therefore,
it is indispensable to gain a better understanding of the
mechanisms of GC proliferation. MiRNAs related to
tumor proliferation control GC progression and metas-
tasis. Low expression of serum miR-203 is found signifi-
cantly associated with poor disease-free and overall
survival in patients with GC [18] and non-small cell lung
cancer (NSCLC) [27]. But, the prognostic significance of
miR-203 expression in human GC tissues and its under-
lying molecular mechanisms have been seldom reported.
In the present study, we screened the differentially-
expressed miR-203 between GC tissues and the ANTTs
and verified that miR-203 expression was significantly
downregulated in GC tissues. Then, we found that miR-
203 expression was negatively correlated with the tumor
Fig. 5 PIBF1 overexpression attenuated miR-203-induced inhibition of GC growth and Akt signaling. a Lentivirus-mediated PIBF1 overexpression
was used to transfect into miR-203-treated GC cells for 72 h, and cell proliferative activity was examined by MTT assay. b The protein expression
levels of PIBF1 and downstream factors including p-Akt, Akt, EGFR, and STAT3 were detected by western blotting. c Lentivirus-mediated PIBF1
was used to transfect into miR-203-treated GC cells for consecutive five days, and cell proliferative activity was examined by MTT assay.
**P < 0.01, *P < 0.05
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size in GC patients and presented the independent risk
factors of OS and recurrence rate in GC patients. Our
findings suggested that miR-203 might have the poten-
tial to serve as a biomarker for prognosis and recurrence
in GC patients.
MiRNAs have been fused into carcinogenic programs
by regulating genes at post-transcriptional level and
involved in tumor development and progression. Evi-
dence shows that miR-203 acts an important role in the
regulation of tumor proliferation, migration and inva-
sion. Some studies indicate that miR-203 overexpression
suppresses cell growth and metastasis via targeting dif-
ferent genes in different tumor tissues, such as targeting
TBK1 in Osteosarcoma [28], ADAM9 and long non-
coding RNA HULC in hepatocellular carcinoma [29],
Rap1A in prostate cancer [30], Ran and miR-21 in esopha-
geal cancer [31]. However, few studies show that miR-203
may function as the carcinogenic factor via enhancing cell
proliferation, migration and invasion by degrading SIK1 in
pancreatic cancer [32]. In the present study, we further
evaluated the functions and targeted genes of miR-203 in
GC cells and found that miR-203 overexpression inhibited
cell proliferation and colony formation, while its knock-
down promoted cell proliferation in GC cells, indicating
miR-203 as a tumor suppressor in GC.
Progesterone-induced blocking factor (PIBF) is an im-
munomodulatory protein acting the role in the regulation
of the immune response in the reproductive system. PIBF1
has been reported overexpressed in various tumors and is
correlated with the growth, invasion and metastasis in
cancer patients [33, 34]. Our studies showed knockdown
of PIBF1 reduced cell proliferation and colony formation,
and PIBF1 was predicted to be a direct target of miR-203
by bioinformatics analysis and was validated by western
blotting in GC cells. Studies have shown that PIBF1 pro-
motes tumor growth and invasion by regulating Akt, ERK,
and STAT3 signaling pathways [35]. We found that miR-
203 exerted targeted inhibition of PIBF1 expression and
downregulated its downstream p-Akt, its knockdown
upregulated the expression of PIBF1 and p-Akt, and the
restoration of PIBF1 abrogated the anti-proliferative ef-
fects of miR-203 in GC cells, suggesting that miR-203
might inhibit GC proliferation via targeting PIBF1/Akt
signaling.
Conclusions
In conclusion, our findings indicate that decreased
expression of miR-203 is associated with tumor size,
poor prognosis and recurrence in GC patients, and
miR-203 overexpression suppresses the GC growth by
targeting PIBF1/Akt signaling, suggesting that miR-
203 may have the important therapeutic potential for
treatment of GC.
Fig. 6 MiR-203 overexpression inhibited GC growth in vivo. a Representative photographs of GC tissues derived from HCG-27-miR-203 or HCG-
27-miR-NC cells in nude mice. b The growth curve showed that miR-203 inhibited gastric tumor growth compared with the miR-NC group.
c, d At the end of the experiment, the average volume and weight of gastric tumors in miR-203 group were significantly lower than those of
the miR-NC group. e IHC analysis of the protein expression of PIBF1, p-Akt, Akt, EGFR, and STAT3 in gastric tumors. The data were shown as the
means ± SD of three independent experiments. *P < 0.05, image scale: 50 μm
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Additional files
Additional file 1: Table S1. Univariate and Multivariate Analyses of
Factors Associated with Overall Survival. (DOC 32 kb)
Additional file 2: Table S2. Univariate and Multivariate Analyses of
Factors Associated with Cumulative Recurrence. (DOC 32 kb)
Additional file 3: Figure S1. MiR-203 knockdown enhanced the
proliferation in GC cells. (A) Cell proliferative activity of GC cells was
examined by MTT assay at the indicated time after seeding. (B) Effect of
miR-203 knockdown on colony formation of GC cells. *P < 0.05. (C) The
protein expression levels of PIBF1 and downstream factors including
p-Akt, Akt, EGFR, and STAT3 were examined by western blotting.
(TIF 11367 kb)
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